Evidence map›Paper›PMID 42343319›Full record

ReviewClinical epigenetics2026

Epigenetic collapse establishes transcriptional bottlenecks in malignant rhabdoid tumor.

Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo

Abstract readReview
In one paragraph

Review in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tatsuya MasudaDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.
Takayoshi WatanabeDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.
Toshinori OzakiDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.
Yasuhiko KamikuboDivision of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan. ykamikubo@chiba-cc.jp.

Funding

Japan Society for the Promotion of Science 22K07168, 24K11817, 25K11143, 25K11216, and 25K19717
6 · The paper itself

Abstract

Malignant rhabdoid tumor (MRT) is an aggressive pediatric cancer defined by biallelic loss of SMARCB1 and characterized by an unusually simple mutational landscape. Despite the absence of recurrent activating oncogenic mutations, MRT exhibits highly malignant behavior, creating a clinical paradox. Loss of SMARCB1 disrupts SWI/SNF-mediated chromatin organization, leading to enhancer redistribution and reorganization of transcriptional control. MRT therefore provides a defined model to examine how structural disruption of chromatin regulation sustains tumor maintenance in the absence of mutation-driven signaling activation. We propose that this epigenetic collapse reduces regulatory diversity and concentrates control of essential survival and cell-cycle programs within limited transcriptional nodes. We define this structural state as transcriptional bottleneck formation, in which tumor viability depends on concentrated transcriptional control rather than recurrent genetic alteration. Bottleneck nodes are characterized by enriched chromatin occupancy at survival and cell-cycle genes, limited compensatory regulation, and functional sensitivity to perturbation. In MRT, members of the RUNX family illustrate a representative concentrated transcriptional node linking chromatin reorganization to regulation of BIRC5 and related survival genes. This disease-focused perspective supports an architecture-centered therapeutic strategy aimed at disrupting concentrated transcriptional control. Identification of biomarkers reflecting this architectural state may facilitate selection of bottleneck-directed interventions in MRT.

Indexed as

Epigenesis, GeneticRhabdoid TumorSMARCB1 ProteinChromatinChromatin Assembly and DisassemblyGene Expression Regulation, NeoplasticHumansTranscription, GeneticChromatinSMARCB1 ProteinSMARCB1 protein, humanChromatin remodelingEnhancer architectureEpigenetic collapseMalignant rhabdoid tumorSMARCB1Transcriptional bottleneck formation

Identifiers

PMID42343319
PMCPMC13551687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.